On Monday night, Senators Mike Lee (R-Utah) and Jerry Moran (R-Kansas) announced their opposition to the Republican healthcare reform bill, the Better Care Reconciliation Act (BCRA).
On Monday night, Senators Mike Lee (R-Utah) and Jerry Moran (R-Kansas) announced their opposition to the Republican healthcare reform bill, the Better Care Reconciliation Act (BCRA). Senators Lee and Moran joined Senators Rand Paul (R-Kentucky) and Susan Collins (R-Maine) in saying that they would not support the bill, leaving Senate Majority Leader Mitch McConnell 2 votes short of the number needed to pass the act. This final blow to the BCRA comes after a vote on the bill was delayed in order to allow Senator John McCain (R-Arizona) to recover after undergoing surgery last week.
In his formal announcement of his opposition to the bill, Senator Moran said, “There are serious problems with Obamacare, and my goal remains what it has been for a long time: to repeal and replace it. This closed-door process has yielded the BCRA, which fails to repeal the Affordable Care Act (ACA) or address healthcare’s rising costs. For the same reasons I could not support the previous version of this bill, I cannot support this one.” Senator Lee said in his own statement that he could not vote in favor of the act because it “doesn’t go far enough in lowering premiums for middle class families; nor does it create enough free space from the most costly Obamacare regulations.”
Senator McConnell said that “the effort to repeal and immediately replace the failure of Obamacare will not be successful,” and added that Republicans now plan to repeal the ACA without immediately proposing new legislation to take its place. Such a move could have cascading consequences for the biosimilars industry; the Biologics Price Competition and Innovation Act, which established an accelerated approval pathway for biosimilar products, was passed into law as part of the ACA. The Washington Post reports, however, that many centrist Republican lawmakers are opposed to a straight repeal of the Obama-era legislation, and that such a repeal would be unlikely to pass.
The uncertain future of Republican healthcare reform has created an opportunity for the FDA Reauthorization Act, passed by the House last week, to reach a vote more quickly. Senator McConnell placed the FDARA on the Senate’s calendar on Monday, moving the bipartisan bill a step closer to its expected passage. While McConnell has not yet disclosed a date for a Senate vote on the FDARA, some have suggested that the failure of the BCRA could allow lawmakers time to vote on the reauthorization plan for user fees sooner rather than later.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
August 21st 2024Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
August 19th 2024CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.